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ABSTRACT 
 
Cloning and Expression of Equine NF-B2. (May 2008) 
Negin Mirhosseini, B.A., Shahid Bahonar University 
Chair of Advisory Committee: Dr. Susan Payne  
 
 Equine infectious anemia virus (EIAV) is a macrophage-tropic retrovirus that 
causes persistent disease in horses and ponies. In addition to its structural proteins, EIAV 
encodes four regulatory/accessory genes, tat, rev, ttm, and S2. It has been documented 
EIAV S2 gene expression is essential for disease expression of EIAV.  Using a yeast 
two-hybrid assay, it was shown that S2 protein interacts with human NF-B2. NF-B2 
plays a key role in the alternative or non-canonical NF-B pathway. In order to 
determine if the interaction of S2 with NF-B2 might be relevant to equine disease, a 
cDNA representing full length equine NF-B2 was generated in our laboratory using 
PCR and rapid amplification of cDNA ends. To our knowledge this is the first time that 
equine NF-B2 cDNAs have been recovered and characterized. The sequence of equine 
NF-B2 was 95% homologous to human overall, however a major difference was found 
in the ankyrin repeat region where protein-protein interactions occur. Two splice 
variants of equine NF-B2 were found that correspond to splice variants of human NF-
B2.  We tested the interaction of EIAV S2 and equine NF-B2 using the yeast two 
hybrid system (Y2H) and co-immunoprecipitation. Unfortunately we were not able to 
detect an interaction between EIAV S2 and equine NF-B2 in either system. Despite this 
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result, NF-B2 is an important component in the immune response so we examined its 
expression in equine macrophages.  Moreover we were interested to know if EIAV 
might affect expression levels of equine NF-B2, as NF-B2 is a target of other viruses. 
Hence, the expression level of equine NF-B2 was measured in uninfected and infected 
primary equine monocyte- derived macrophage (eMDM). Using quantitative PCR we 
determined that equine NF-B2 gene expression is decreased in eMDM after 3 days post 
plating, about the time that monocytes start to differentiate into mature macrophages. 
However EIAV infection of eMDM upregulated the expression level of NF-B2. 
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CHAPTER I 
INTRODUCTION  
1
 
Equine Infectious Anemia Virus (EIAV) 
Equine infectious anemia (EIA) was first described in France in 1843. In 1904, it 
was determined that the disease was associated with a filterable agent that causes 
infection in horses and ponies.  This was the first time that an animal disease was 
identified with a viral etiology (Leroux et al., 2004). The viral agent of EIA, equine 
infectious anemia virus (EIAV) is a member of the family Retroviridae. EIAV is a 
macrophage-tropic retrovirus (Leroux et al., 2004) and it has been shown that monocyte 
maturation has a key role in the regulation of EIAV expression. Peripheral blood 
monocytes allow viral entry and reverse transcription of viral RNA but do not allow 
EIAV replication (Maury, 1994). It has been shown equine lentivirus receptor-1 (ELR1), 
related to the family of TNF receptor proteins, serves as the EIAV receptor. ELR1 is 
expressed in various equine cells permissive for EIAV entry in vitro, including 
monocytes and macrophages (Zhang et al., 2005).  
EIAV is transmitted mechanically by either an insect vector or an infected 
needle. EIAV causes a persistent infection which is typically classified in three defined 
stages: acute, chronic, and long-term asymptomatic (Leroux et al., 2001).  Initial 
exposure of an animal to a virulent strain usually results in an acute disease (Leroux et 
al., 2004; Maury, 1998). The acute stage of disease usually resolves within a few days 
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and later the animal may experience the chronic stage of disease, characterized by the 
recurrence of clinical symptoms associated with cycles of viremia with fever, anemia, 
edema, thrombocytopenia, and various wasting syndromes (Leroux et al., 2004; Leroux 
et al., 2001; Payne et al., 1994). Some studies have shown that the asymptomatic stage 
of infection is due to control of virus replication by host immune response rather than 
virus attenuation (Hammond et al., 2000). This makes EIAV a practical model to 
examine the natural immunological control of lentivirus replication and disease 
(Hammond et al., 2000; Oaks et al, 1998).  
EIAV Genome and Viral Proteins 
The EIAV genome is the smallest and simplest of the Lentiviral genomes. This 
makes EIAV a useful model system to examine the contribution of specific viral genes 
in lentivirus replication, persistence, and pathogenesis (Leroux et al., 2004). Like other 
retroviruses, the EIAV genome contains two copies of single-stranded RNA which is 
capped and polyadenylated (Strauss et al., 2002). The 5 and 3 ends of genome contains 
the long terminal repeats (LTRs) which are composed of three segments namely U3 
(unique sequence at 3end), R (repeat sequence) and U5 (unique sequence at 5end). 
LTRs are necessary for transcriptional initiation and polyadenylation of the viral RNA 
(Muary, 1998). The U3 region contains several elements important for viral transcription 
(Leroux et al., 2004; Payne et al., 1999). Studies have been shown that the U3 ets sites 
are essential in the regulation of EIAV transcription in macrophage (Maury, 1994). 
Similar work has revealed the fact that both envelope and long terminal repeat (LTR) 
influence cell tropism and virulence (Maury et al., 2005).  
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Similar to other retroviruses, EIAV uses gag, pol and env genes to encode 
structural proteins which are common to all retroviruses (Fig. 1A). In addition, four 
regulatory accessory proteins are encoded by virus. These proteins are Tat, Rev, Ttm, 
and S2 (Leroux et al., 2004; Beisel et al., 1993; Fagerness et al., 2006) (Fig. 1A).  The 
locations of different gene products in the virion are illustrated in Fig. 1B.   
Gag Gene 
EIAV gag (group-specific antigen) encodes a large Gag- precursor (Pr55gag) 
protein, which is translated from the full-length viral messenger RNA (Leroux et al., 
2004). The Gag polyprotein has a key role in assembly and budding of retroviruses from 
host cells. Upon or immediately after budding of virus particles from host cells, the 
Pr55gag is cleaved by viral protease into four major internal structural proteins: the 
membrane–interacting matrix (MA), the capsid (CA), the RNA binding nucleocapsid 
(NC) P11, and P9  (Leroux et al., 2004; Hatanaka et al., 2002; Freed, 1998). The general 
structure of the main Gag proteins (MA, CA, and NC) in the Gag precursor and in the 
virion is highly conserved among retroviruses (Freed, 1998). MA, which forms the N-
terminal domain of the Pr55Gag, is associated with the inner face of the envelope and it 
may have a role in carrying the viral genome into the nucleus after infection (Leroux et 
al., 2004; Hatanaka et al., 2002; Freed, 1998). In the mature virion, capsid forms a shell 
around the NC/RNA complex (Freed, 1998). The CA domain of Pr55Gag plays an 
important role in virus assembly and the mature CA protein is involved in early 
postentry steps. In the virion, NC forms a core which is tightly associated with the viral 
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RNA (Fig. 1B). The NC domains of retroviral Gag proteins were known early on as 
playing a key role in RNA binding and encapsidation (Freed, 1998). 
Pol Gene 
Pol is located between gag and tat (Fig. 1A). The pol open frame overlaps with 
C-terminus of gag by 251 bases (Stephens et al., 1986). Along with gag products, pol 
products are translated from full length mRNA. These proteins carry out a variety of 
enzymatic activities such as reverse transcription and RNA degradation (RT-RNaseH), 
integration (IN), dUTP hydrolysis, and proteolysis (p12). (Leroux et al., 2004; Strauss et 
al., 2002).  
Reverse transcriptase-RNaseH is important for the synthesis of viral DNA. Once 
the EIAV enters the cell, reverse transcription takes place in a subviral particle in order 
to generate a full length, linear double stranded (ds) DNA.  Integrase is essential for 
insertion of the viral genome (dsDNA) into the host’s chromosome through a single 
recombinational event (Strauss et al., 2002).   
Viral dUTPase activity hydrolyzes dUTP to dUMP to provide a substrate for 
biosynthesis of dTTP which reduces the chances of misincorporation of dUTP into 
DNA. EIAV dUTPase is required for efficient viral replication in the non-dividing 
equine macrophages, where cellular dUTPase is expressed at low levels, but is 
dispensable in permissive cell lines where cellular dUTPase is abundantly expressed 
(Shao et al., 1997; Threadgill et al., 1993).  
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Fig. 1.  Genome and mature virion of EIAV.  (A) Viral genome schematic with open reading frames indicated by boxes.  
(B) Cartoon of EIAV virion showing the location of the structural proteins.  
 
B 
A 
gp45 (transmembrane) 
gp 90 
(surface) 
Matrix 
Membrane 
Nucleocapsid 
Viral RNA 
Integrase 
Reverse Transcriptase  
EIAV Virion 
 
LTR  Tat 
Gag 
Pol 
Env 
Tat Rev Rev 
S2 
LTR  
  
6 
 
Viral protease (p12) is needed for the processing of Pr55gag which accurse after 
during assembly of progeny virions (Strauss et al., 2002).  
Env Gene 
The major open reading frame for env starts at nucleotide 1253 and continues for 
862 codons. Env encodes the surface (SU) or gp90 and transmembrane (TM) or gp45 
glycoproteins, which are incorporated into virions during virus budding from the plasma 
membrane (Leroux et al., 2004; Freed, 1998). Envelope glycoproteins of EIAV are a 
target for neutralizing antibody. It has been suggested that mutation in the envelope gene 
is a way for the virus to escape from immune responses, resulting in viral replication and 
periodic clinical cycles (Pang et al., 1997).     
Tat Gene 
Tat, located between pol and env, encodes a protein with both structural and 
functional homology to the Tat protein of HIV-1. Tat protein is a monomeric protein of 
75 amino acids which is encoded by at least three alternatively spliced transcripts 
(Willbold et al., 1994); Rosin-Arbesfeld et al., 1993) (Fig. 1A). Tat is a transactivator of 
transcription of the long terminal repeat (LTR) region that is required for viral 
expression (Maury et al., 1994). Interactions between Tat and trans-activation responsive 
(TAR) elements, in the form of RNA stem-loops, enhance viral gene expression 
(Arbesfeld et al., 1998; Derse et al., 1991). 
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Rev Gene 
Rev encodes a protein similar to HIV Rev, which regulates viral gene expression. 
Rev mediates mRNA transport from the nucleus to the cytoplasm through a Rev 
responsive element (RRE) positioned near the end of env (Leroux et al., 2004; Fagerness 
et al., 2006). Moreover, Rev variation may affect virus expression and long-term viral 
persistence during the long-term infection (Belshan et al., 1998). 
Ttm Gene 
Ttm encodes a novel Tat-TM fusion protein, a 27-kDa accessory protein, which 
is encoded by the first exon of tat and portion of the 3-terminus of the transmembrane 
(TM) protein-coding region (Fagerness et al., 2006; Beisel et al., 1993).  The carboxy 
terminus of lentiviral TM proteins has important roles in viral infectivity, growth 
kinetics, and cytopathology, suggesting that Ttm plays an important role in the EIAV life 
cycle (Beisel et al., 1993). 
S2 Gene 
  The EIAV S2 gene, located between the second exon of tat and env, and 
overlapping the N-terminus of the env, encodes a 65 amino acid protein (Leroux et al., 
2004; Yoon et al., 2000). The S2 protein contains 3 amino-acid motifs which are highly 
conserved among different isolates of EIAV. These motifs are GLFG (putative 
nucleoporin motif), PXXP (putative SH3 domain binding motif), and RRKQETKK 
(putative nuclear localization sequence) (Li et al., 2000) (Fig.2).  
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Fig. 2. Amino acid alignment of the S2 protein of different strains.  Conserved 
domains are: nucleoporin (brown), N-myristylation (red), phosphorylation (green), SH3-
binding (blue), and Nuclear localization (pink). 
 
There is evidence showing that S2 is mainly localized in the cytoplasm and is 
coprecipitated with the EIAV Gag precursor (Yoon et al., 2000). Li et al. (1998) 
investigated the role of S2 in virus replication in vitro using an infectious molecular viral 
clone, designated by EIAVUK. By using various EIAVUK mutants lacking S2 and 
examining the replication kinetics of these mutants in equine macrophage cells, they 
have concluded that the EIAV S2 gene is not essential for viral infection and replication 
in target cells in vitro. However, other studies have illustrated that S2 gene expression is 
essential for viral replication and disease expression of EIAV in infected horses 
(Fagerness et al., 2006; Li et al., 2000). In order to show that S2 is required for disease 
expression, Fuller and his colleagues (Fagerness et al., 2006) inoculated ponies with 
either wild type EIAV (EIAV17), which is highly virulent, or with the mutant EIAV 
(EIAV17S2) in which S2 was deleted.  The EIAV17-infected ponies showed severe 
febrile episodes with 40.5 to 41 °C body temperatures by 2 weeks post-infection. In 
addition to febrile episodes, these ponies also experienced severe thrombocytopenia. In 
contrast, the EIAV17S2 –infected ponies did not experience a febrile episode or platelet 
drop within 2 weeks post-infection. No clinical signs were observed in these ponies 
through a 180-day observation period (Fagerness et al., 2006). 
CONSENSUS           MGLFGKGVTWSASHSMGGSQGESQPLLPNSQKNLSVRR--TQCFNLIVIIMTVRTAWQNRRKQETKK
AF247394            MGLFGKGVTWSASHSMGGSQGESQPLLPNSQKNPSMRK--TQCFNLIVIIMTVRTAWQNRRKQETKK
EIAV19/17 MGVFGKGVTWSASHSMGESQGESQPLLPNSQKNLSVRR--TQCFNLIVIIMTVRTAWQNRRKQETKK
AB008197strainV     TELFGKGVTWSASHSMGGSQGESQPLLPNSQKNLSVRG--IQCFNLIVIMMTVRTAWQNRRKQETKK
AB008196Zhenget     MGLFGKGVTWSASHSMGGSQGESQPLLPNSQKNLSVRG--IQCFNLIV-MMTV--AWQNRRKQETKK
AF327878Tdonkey     MGLFGKGVTWSALHSVGVSQGEYQPLSPNKQNQQTHRKEIIWYINPIVIMIAIKKKWQRQETQDTKKK
AF327877Liaonin     MGLFGKGVTWSALHSMGVSQGEYQPLSPNKQNQQTHKKGITWYINPIVIMTAIKQKWQRQETQDTKKK
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How S2 functions to modulate replication and virulence is unknown. In order to 
address this question, we investigated the interaction of S2 with host cellular proteins. A 
commercially available human spleen cDNA library was used in a yeast two hybrid 
screen to elucidate any possible interactions between cellular proteins and S2. Our 
laboratory results have shown that S2 interacts with three different human proteins (L. 
Covaleda, unpublished results). These are human OS-9, which is the product of a gene 
frequently amplified in osteosarcoma (Kimura et al., 1998), human Tat-binding protein-1 
(TBP-1), which is a component of the 19S regulatory complex of the proteasome (Corn 
et al., 2003), and Nuclear Factor Kappa B p100/p52 (NF-B2), which is a transcription 
factor known to play a role in the regulation of immune and inflammatory responses.  
Nuclear Factor Kappa B (NF-B) 
Even though it has been more than two decades since the discovery of NF-B, it 
is still an exciting area of research and study (Baldwin, 2001). NF-B or Nuclear Factor 
Kappa B is a transcription factor which plays a key role in regulating immune and 
inflammatory responses in both innate and adaptive immunity (Baldwin, 2001; 
Pomerantz et al., 2002; Beinke et al., 2004). NF-B is involved in a variety of viral 
diseases. Studies show that the NF-B pathway is an attractive target for many 
pathogenic viruses such as HIV-1, the human T-cell leukemia virus HTLV-1, influenza 
virus, hepatitis B and C viruses, and herpesviruses. These viruses are able to hijack the 
NF-B pathway and control it to their own benefit (Santoro et al., 2003; Tato et al., 
2002). Typically, mammalian cells express five different NF-B proteins: RelA (p65), 
RelB, c-Rel, NF-B1 (p50), and NF-B2 (p52). These proteins share 300 amino acids 
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within their N-terminal Rel homology domain (RDH) that facilitates their binding to the 
specific DNA sequence named the B site (Heusch et al., 1999; Xiao et al., 2006).  
There are two pathways that lead to activation of NF-B: The canonical and non- 
canonical pathways.  
NF-B1/p50 is involved in the canonical pathway. This pathway, which has been 
also known as the classical pathway, is activated by a large variety of stimuli such as 
mitogens, cytokines (for example, tumor necrosis factor alpha (TNF-) and interleukin 
one (IL-1)), microbial components (for instance, lipopolysaccharide (LPS)), and DNA 
damage. Upon stimulation, a specific IB kinase (IKK) is activated. The activation of 
IKK initiates phosphorylation of IB proteins which triggers their ubiquitination.  After 
degradation of IB by the 26S proteasome, the NF-B dimer is released and translocated 
into the nucleus to induce gene expression (Xiao et al., 2006) (Fig. 3A).  
NF-B2 encodes p52 and p100. The expression of p52 is normally at low levels 
in many cells. However p52 is characteristically expressed at higher levels in dendritic 
cells, T cells, and macrophages (Heusch et al., 1999).  While the classical pathway of 
NF-B activation is mainly based on degradation of IB proteins, the alternative 
pathway of NF-B activation is based on p100 processing (Xiao et al., 2006). 
Unprocessed p100 acts as an IB protein due to a cluster of ankyrin repeats in its C-
terminal domain. Therefore, the processing of p100 to p52 regulates the alternative NF-
B activation pathway (Xiao et al., 2006). Principally, the processing of p100 to p52 is 
upon the activation of “NF-B binding kinase” (NIK). NIK, then activates IB kinase 1 
(IKK1) and recruits it into the p100 to trigger ubiquitination of p100. Subsequently, 
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ubiquitinated p100 is processed to p52 by the 26S proteasome (Xiao et al., 2006).  After 
that, p52 is translocated into the nucleus in association with other Rel subunits to 
activate a variety of genes (Beinke et al., 2004) (Fig. 3B).  
Many studies indicated that the alternative NF-B pathway controls the 
expression of the genes involved in B-cell proliferation and function, medullary thymic 
epithelial cell development, humoral immune responsiveness, and splenic structural 
design as well as cell proliferation and survival (Pomerantz et al., 2002; Tato et al., 
2002; Zhang et al., 2006; Xiao et al., 2006).   There are a number of receptors that are 
involved in activation of the alternative pathway, such as: BAFF, a B-cell activating 
factor, CD40L which stimulates B-cell proliferation and secretion of all immunoglobulin 
isotypes in the presence of cytokines, RANKL, a receptor activator of NF-B ligand, 
lymphotoxin- receptor (LTR), and LTR.  
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Fig. 3. NF-B pathway.  (A) The canonical (classical) NF-B pathway. (B) The Non-
canonical (alternative) NF-B Pathway. 
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Interestingly, some viral proteins are also able to induce the alternative pathway. 
These viruses hijack the host’s alternative NF-B pathway for their replication and this 
may influence their oncogenic properties (Dejardin, 2006).  For example, human T-cell 
leukemia virus type I (HTLV-I), Epstein-Barr virus (EBV), and Kaposis sarcoma-
associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) encode the viral proteins 
Tax, LMP1, and K13/v-FLIP, respectively that can process p100 and activate the 
alternative NF-B pathway. Tax directly binds to the p100 and recruits IKK1 to p100 to 
trigger p100 processing. LMP1, encoded by EBV, mimics CD40 signaling in B cells and 
activates the NF-B2 pathway. The mechanism of activation of NF-B by K13/v-FLIP, 
encoded by KSHV/HHV-8 is similar to Tax (Xiao et al., 2006; Dejardin, 2006). 
Moreover, there are some other diseases that are also related to deregulated 
activation of the alternative NF-B pathway.  For example, development of various 
lymphomas/leukemia such as cutaneous T-cell lymphomas, B-cell non-Hodgkin 
lymphomas, chronic lymphocytic leukemia and myelomas are due to aberrant activation 
of the alternative NF-B pathway. In addition, there are some autoimmune diseases that 
are linked to activation of the alternative NF-B pathway, such as systemic lupus 
erythematosus, Sjogrens syndrome, rheumatoid arthritis and autoimmune diabetes (Xiao 
et al., 2006).  
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CHAPTER II 
CLONING EQUINE NF-B2 
 
Introduction  
Use of the yeast two hybrid system to reveal host cell proteins interacting with 
EIAV S2 led to the identification of human NF-B2 (L. covaleda, unpublished data). To 
follow up on this finding and determine if interaction of S2 and NF-B2 was important 
for EIAV pathogenesis, equine NF-B2 was cloned.  
The general methodology used was to generate a fragment of equine NF-B2 by 
PCR using degenerate oligonucleotides representing conserved regions of the NF-B2 
gene. Rapid amplification of cDNA ends (RACE) was then used to obtain the 5 and 3 
ends of the equine NF-B2 cDNA. The RACE system is a procedure for amplification of 
nucleic acid sequences from a messenger RNA template between a defined internal site 
and unknown sequences at either the 3 or the 5 end of the mRNA (Zhang et al, 2006). 
Finally, an overlap PCR extension strategy was used to piece together a full-length 
equine NF-B2 cDNA.   
Materials and Methods 
Isolation of white blood cells and establishment of equine monocyte derived macrophage 
(eMDM) cell cultures 
Whole blood in the volume of 500 ml was collected from EIAV-negative horses 
into an anticoagulant citrate dextrose solution blood collection bottle (The Metrix 
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Company, Dubuque, Iowa 52002, USA). To obtain the buffy coats blood was 
centrifuged at 700 ×g for 20 min. Then eMDM were separated by density gradient 
centrifugation using HybriMax histopaque (d = 1.077 g/cm3) cushion (Sigma, St. Louis, 
MO). The eMDM were washed four times with Dulbecco's Ca2+- and Mg2+-free PBS 
(Sigma, St. Louis, MO), 5% adult horse serum (endotoxin and EIAV tested, 
Invitrogen/Gibco, Carlsbad, CA) and 1% penicillin–streptomycin solution (Sigma, St. 
Louis, MO). The eMDM were seeded in HYQ MEM Alpha Modification 1X (Cat. 
Sh3026565.01), containing 1% (v/v) penicillin and streptomycin, 10% equine bovine 
serum, 1% NEAA (non-essential amino acids), 25 mM HEPES, and 1% L- Glutamine. 
Then the cells were incubated at 37°C in a 5% CO2 atmosphere incubator.  
Generating the internal fragment of eq.NF-B2 
A fragment of NF-B2 was initially cloned as follows: after 2 to 3 days, when 
monocytes had differentiated to the macrophage, the cells were harvested and washed 
with PBS, and then resuspended in sufficient amount of lysate buffer containing 1X Halt 
Protease. Afterwards, total RNA was extracted from eMDM cells using the Qiagen 
RNeasy Mini kit (Cat. No. 74104). First strand cDNA was synthesized from total RNA 
with Reverse Transcriptase II (Invitrogen) and an oligo dT primer. Two PCR primers, 
MH NF-B forward: 5-CGATTTCGATATGGCTGTGA-3 and MH NF-B reverse: 5-
GGTGRRCMCAGCTTCTCTG-3, designed based on homologies among human 
p49/p100 (accession #:  NM_002502), mouse NF-B2 (accession #: NM_019408), and 
canis NF-B2 (accession #:  (NW_876285) sequences were used to generate a 2498 bp 
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internal fragment of equine NF-B2. The internal fragment was cloned into the TOPO® 
vector (Invitrogen TOPO TA Cloning Kit for Sequencing) and sequenced. 
Rapid amplification of cDNA ends (RACE) 
In order to clone full length NF-B2, we performed RACE using InvitrogenTM 5´ 
RACE System for Rapid Amplification of cDNA Ends, Version 2.0. In brief, three 
specific primers: GSP1 (5-GTCACAAAGCAGATAA-3), GSP2 (5-
GGGAGATAACTGGCTTCAGGGGCAGGGAGAA-3), and GPS3 (5-
CCCTCCTCCTTGACCTACAACCCCTACCAGT-3) were synthesized based on the 
cDNA sequence obtained by sequencing the products of the internal amplification. For 
each 5- (primers GSP1 and GSP2) and 3-RACE (primer GSP3), the cDNA was 
synthesized and amplified according to the manufacturer's protocol. The conditions for 
amplifying the 5 end included an initial denaturation at 94 °C for 3 minutes, thirty 
cycles at 94 °C for 30 sec, 55 °C for 30 sec, and 72 °C for 1 minute, followed by a final 
extension at 72 °C for 7 minutes. PCR conditions for amplifying the 3 end were as 
follows: one initial denaturation at 94 °C for 3 minutes, thirty cycles at 94 °C for 30 sec, 
62 °C for 30 sec, and 72 °C for 1 minute and 40 sec, followed by a final extension at 72 
°C for 5 minutes.  PCR products of 5- and 3-RACE were visualized after 
electrophoresis in a 0.9% agarose gel containing ethidium bromide. 5 and 3 products 
were cloned into a TOPO vector (Invitrogen) and sequenced.  
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Generating full length equine NF-B2 cDNAs using overlap PCR extension 
After obtaining the 5 and 3 ends of equine NF-B2, these two fragments were 
combined with an internal fragment by overlap PCR extension to obtain a full length 
cDNA clone. A short internal fragment (SIF), designed to overlap the 5 and 3 end 
segments by 71 and 65 nucleotides, respectively, to enhance the extension  process, was 
made using Short NF-B forward (5-CCTGCGCTTCTCTGCCTTCCTT-3) and Short 
NF-B reverse (5-CCTCCCGGGTAGCAGCCCATT-3) primers. PCR conditions used 
to generate the SIF were as follows: Initial denaturation at 94 °C for 3 minutes, thirty 
cycles at 94 °C for 30 sec, 59 °C for 30 sec, and 72 °C for 1 minute, followed by a final 
extension at 72 °C for 5 minutes. The SIF, 5 end, and 3 end were first amplified by 
PCR and each fragment was gel purified. A master mix reaction without any primer was 
made for joining the 5 end and internal fragment together. The PCR conditions for this 
step were as follows: initial denaturation at 94 °C for 3 minutes, ten cycles at 94 °C for 
30 sec, 72 °C for 30 sec, and 72 °C for 4 minutes, followed by a final extension at 72 °C 
for 7 minutes. The following primers were then added to amplify the joined fragment:  5 
end primer Forward (5-CCCAGAGACATG GAGAGTTGCTA-3) and Short NFKB 
reverse (5-CTCCCGGGTAGCAGCCCATT-3). The PCR conditions were as follows:  
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initial denaturation at 94 °C for 3 minutes, thirty cycles at 94 °C for 30 sec, 64 °C for 30 
sec, and 72 °C for 3 minutes, followed by a final extension at 72 °C for 7 minutes. A 
PCR master mix reaction without any primer was then used to join the 3 end to generate 
full length equine NF-B2. The PCR conditions for this step were as previously 
described. The primers: 5 end primer Forward (5- 
CCCAGAGACATGGAGAGTTGCTA-3) and 3 race inner reverse (5-
AGAAAGCTGGGTGGCTGCTGAGTGGGTGACAGTT-3) were then added to PCR 
reaction in order to amplify the joined piece. The PCR conditions for this step were the 
same as amplifying the 5 end and internal fragment, except that the extension time was 
increased to 4 minutes. Full length equine NF-B2 cDNA was visualized after 
electrophoresis in a 0.8% agarose gel containing ethidium bromide, and gel purified. Full 
length equine NF-B2 was later cloned into a TOPO vector (Invitrogen), sequenced and 
compared to human NF-B2. 
The summary of all primers and PCR conditions for different steps for generating 
the full length equine NF-B2 are shown in Tables 1 and 2, respectively.  
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Table 1  
Primers to generate full length NF-B2 
The 3 race inner reverse primer has some extra nucleotides, which are not in the sequence of 3 end (shown as bold letters). 
This oligo, a part of attB Primer Sequence, is necessary for inserting the PCR product into a pDONRTM using recombination. 
This vector can be used in the yeast two hybrid system.  
 
 
Primer Sequence 
GSP1 5-GTCACAAAGCAGATAA-3 
GSP2 5-GGGAGATAACTGGCTTCAGGGGCAGGGAGAA-3 
GSP3 5-CCCTCCTCCTTGACCTACAACCCCTACCAGT-3 
Short NF-B forward  5-CCTGCGCTTCTCTGCCTTCCTT-3     
Short NFKB reverse 5-CCTCCCGGGTAGCAGCCCATT-3 
5 end  forward 5-CCCAGAGACATGGAGAGTTGCTA-3     
3 race inner  reverse 5-AGAAAGCTGGGTGGCTGCTGAGTGGGTGACAGTT-3    
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Table 2 
PCR condition to generate full length equine NF-B2 
Conditions to amplify 5 end of equine NFB2 (744 bp) 
Step Temperature Time Cycle(s) 
Initial Denaturation 94oC 3 min 1 
Denaturation 94 oC       30 sec 
Annealing 55 oC       30 sec 
Extension 72 oC 1 min 
30 X 
Final Extension 72 oC 7 min 1 
Conditions to amplify 3 end of equine NFB2 (1702 bp) 
Step Temperature Time Cycle(s) 
Initial Denaturation 94oC 3 min 1 
Denaturation 94 oC       30 sec 
Annealing 62 oC       30 sec 
Extension 72 oC 1 min and 40 sec 
30 X 
Final Extension 72 oC 5 min 1 
Conditions to amplify short internal fragment (SIF) of equine NFB2 (633 bp) 
Step Temperature Time Cycle(s) 
Initial Denaturation 94oC 3 min 1 
Denaturation 94 oC       30 sec 
Annealing 59 oC       30 sec 
Extension 72 oC 1 min 
30 X 
Final Extension 72 oC 5 min 1 
Conditions to sew SIF and the 5 end (without primers)  
Step Temperature Time Cycle(s) 
Initial Denaturation 94oC 3 min 1 
Denaturation 94 oC       30 sec 
Annealing 72 oC       30 sec 
Extension 72 oC 3 min 
10 X 
Final Extension 72 oC 7 min 1 
Conditions to  amplify the sewed part (SIF + 5 end) (1306 bp) 
Step Temperature Time Cycle(s) 
Initial Denaturation 94oC 3 min 1 
Denaturation 94 oC       30 sec 
Annealing 64 oC       30 sec 
Extension 72 oC 3 min 
30 X 
Final Extension 72 oC 7 min 1 
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Table 2 continued 
Conditions to join the sewed part to the  3 end in order to generate full length equine 
NF-B2 (adding 4% DMSO as cosolvent, but no primer ) 
Step Temperature Time Cycle(s) 
Initial Denaturation 
Denaturation 
94oC 
94 oC 
3 min 
      45 sec 
1 
10 X 
Annealing 72 oC       30 sec 
Extension 72 oC 4 min  
Final Extension 72 oC 7 min 1 
Conditions to amplify full length equine NF-B2 (2942 bp) 
Step Temperature Time Cycle(s) 
Initial Denaturation 94oC 3 min 1 
Denaturation 94 oC       45 sec 
Annealing 64 oC       30 sec 
Extension 72 oC 4 min 
30 X 
Final Extension 72 oC 7 min 1 
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Results 
Two splice variants of equine NF-B2 were detected 
An internal fragment of equine NF-B2 was cloned using RT-PCR. The size of 
this fragment was 2498 nucleotides. Sequence analysis of several cDNA clones revealed 
two splice variants in this internal region of equine NF-B2 (Fig. 4). The splice variants 
(called 3a and 8a) were identical to reported splice variants of human NF-B2.  In these 
splice variants, which occur at the C-terminus of NF-B2, there is an insertion/deletion 
(indel) of a single alanine. Other differences between the two equine cDNAs are listed in 
Table 3. 
Full length equine NF-B2 was generated using RACE System and overlap extension 
PCR 
The 5 and 3 ends of equine NF-B2, which were 744 and 1702 nucleotides, 
respectively, were generated using RACE (Fig.5A, B). Sequencing of different 5 end 
cDNAs revealed different alleles. In one sequence, named B, the 100th amino acid is 
Aspartic acid (D) and in the other one, named, C, the 100th amino acid is glycine (G) 
(Table 3). A 633 bp SIF was joined to the 5, clone B, and 3 ends (Fig. 5C).  Joining of  
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the internal and 5 end generated a 1306 nucleotide fragment (Fig. 5D). Finally joining 
of this fragment with the 3 end generated full length equine NF-B2 (Fig. 5E, F). The 
size of full length equine NF-B2 was 2942 nucleotides. Fig. 6 shows the nucleotide and 
deduced amino acid sequences of full length equine NF-B2. The spliced region is 
shown in grey shade.   
Equine NF-B2 is about 95% and 92% is homologous to human and mouse NF-B2, 
respectively 
The predicted amino acid sequence of equine NF-B2 was aligned with the 
human and mouse NF-B2 using Biology Workbench 3.2 and the conserved region was 
about 95% homologous with human and 92% with mouse. Interestingly, the highest 
homology (100% identical) was in the IPT_NF-B (DNA-binding) region which is 
shown by white letters highlighted with black in Fig. 7. Black letters highlighted with 
grey show the Rel homology domain which is common among all NF-B proteins. The 
interaction domain of NF-B, the ankyrin repeat region, is shown by white letters 
highlighted with grey. As it can be seen from Fig. 7, the major difference between 
human and equine NF-B2 is in this region (90% identical).  
  
24
 
 
 
Table 3 
Amino acid differences in the sequence of different equine NF-B2 clones 
Amino acid differences in the sequence 
                        
 
 
 
Equine NF-B2 aa 100   aa 491   aa 711 aa 882  
Full length clone B (901 aa) G T A C 
Full length clone C (901 aa) D T A C 
Internal fragment clone 3a (755 aa) N/A T A C 
Internal fragment clone 8a (754 aa) N/A A - G 
Amino acid is designated by (aa), glycine by (G) aspartic acid by (D), threonine by (T), alanine by (A), and cysteine by (C). 
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Fig. 4. Comparison of the splice variants of internal fragment of equine NF-B2. 
Two splice variants in internal region of equine NF-B2 occur at the C-terminus. In one 
splice, 3a, there is an addition of alanine (A). 
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Fig. 5. Full length NF-B2 was generated using rapid amplification of cDNA ends 
(RACE) and overlap extension PCR.  5 and 3 ends generated by RACE system have 
a size of 744 and 1702 bp nucleotides, panels A and B, respectively. A short internal 
fragment, 633 bp nucleotides, was generate to facilitate the sewing process, panel C. 
Short internal fragment was sewed to 5 end to generate a 1306 nucleotide fragment, 
panel D. A full length cDNA of equine NF-B with the size of 2942 nucleotides was 
generated by sewing the 1306 nucleotide fragment to 3 end and gel purified later, panels 
E and F respectively.  
 
 
 
 
 
 
A B C 
D E F 
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      E  A  G  T  G  A  A  A  A  A  G  A  *  N  S  G  K  Q  N  P   
2     gaagccggaaccggagccgccgccgcggcgggcgcctgaaactctgggaaacagaacccg  61 
      A  G  A  T  R  Q  S  R  A  *  P  R  D  M  E  S  C  Y  D  P   
62    gccggagccaccagacagagccgggcctagcccagagacatggagagttgctacgaccca  121 
      G  L  D  G  I  I  D  Y  D  D  F  K  F  N  P  S  I  V  E  P   
122   ggtctggatggtattattgactatgatgatttcaaattcaacccatccattgtggagccc  181 
      K  E  P  A  P  E  T  A  D  G  P  Y  L  V  I  V  E  Q  P  K   
182   aaggagccggccccagagacagctgatggcccctacttggtgatcgtcgaacagcctaag  241 
      Q  R  G  F  R  F  R  Y  G  C  E  G  P  S  H  G  G  L  P  G   
242   cagcgaggcttccgatttcgatatggctgtgaaggcccttcccatgggggactgccaggt  301 
      A  S  S  E  K  G  R  K  T  Y  P  T  V  K  I  C  N  Y  E  G   
302   gcctccagcgagaagggccggaagacttaccccactgtcaagatctgtaactacgaggga  361 
      P  A  K  I  E  V  D  L  V  T  H  S  G  P  P  R  A  H  A  H   
362   ccagccaagattgaggtggacctggtaacacacagtggcccgcctcgtgctcacgcccac  421 
      S  L  V  G  K  Q  C  S  E  L  G  V  C  A  V  S  V  G  P  K   
422   agcctggtgggcaagcagtgctcggagctgggggtctgcgccgtgtctgtgggacccaag  481 
      D  M  T  A  Q  F  N  N  L  G  V  L  H  V  T  K  K  N  M  M   
482   gacatgactgcccaatttaacaacctgggtgtcctgcatgtgaccaagaagaacatgatg  541 
      E  I  M  I  Q  K  L  Q  R  Q  R  L  R  S  R  P  Q  G  L  T   
542   gagattatgatacaaaaacttcagaggcagcgactccgctccaggccccagggccttacg  601 
      E  T  E  R  R  E  L  E  Q  E  A  K  E  L  K  K  V  M  D  L   
602   gagactgagcggcgggagctggagcaggaggccaaggagctgaagaaggtgatggacctg  661 
      S  I  V  R  L  R  F  S  A  F  L  R  A  S  D  G  S  F  S  L   
662   agcattgtgcgcctgcgcttctctgccttccttcgagccagtgacggctccttctccctg  721 
      P  L  K  P  V  I  S  Q  P  I  H  D  S  K  S  P  G  A  S  N   
722   cccctgaagccagttatctcccaacccatccacgacagcaagtctcctggggcctcgaac  781 
      L  K  I  S  R  M  D  K  T  A  G  S  V  R  G  G  D  E  V  Y   
782   ctgaagatttctcgaatggacaagacagctggctctgtgcgaggtggagatgaggtttat  841 
      L  L  C  D  K  V  Q  K  D  D  I  E  V  R  F  Y  E  D  D  E   
842   ctgctttgtgacaaggtgcagaaagatgacattgaggttcgattctacgaggatgatgag  901 
      N  G  W  Q  A  F  G  D  F  S  P  T  D  V  H  K  Q  Y  A  I   
902   aatggatggcaggcctttggggacttctctcccacagatgtccataaacagtatgccatt  961 
      V  F  R  T  P  P  Y  H  K  M  K  I  E  R  P  V  T  V  F  L   
962   gtgttccggacgcctccctatcacaagatgaagattgagcgtcctgtaaccgtattcctg  1021 
      Q  L  K  R  K  R  G  G  D  V  S  D  S  K  Q  F  T  Y  Y  P   
1022  caactgaaacgcaagcgtgggggggatgtctctgactccaaacagttcacctattaccct  1081 
      L  V  E  D  K  E  E  V  Q  R  K  R  R  K  A  L  P  T  F  S   
1082  ctggtagaagacaaggaggaggtgcagcgcaagcggaggaaagccttgcccaccttctct  1141 
      Q  H  F  G  G  G  S  H  M  G  G  G  S  G  G  S  A  G  G  Y   
1142  cagcatttcgggggtggctcccacatgggtggaggctccgggggctcagctgggggttat  1201 
      G  G  A  G  G  G  G  G  S  L  G  F  F  P  S  S  L  T  Y  N   
1202  ggaggagctggaggaggaggtggcagcctcggctttttcccctcctccttgacctacaac  1261 
      P  Y  Q  S  G  A  A  P  M  G  C  Y  P  G  G  G  G  G  A  Q   
1262  ccctaccagtccggcgcggccccaatgggctgctacccgggaggcgggggcggggcgcag  1321 
      M  A  A  G  A  P  S  V  D  A  G  E  E  A  A  E  P  S  A  S   
1322  atggccgccggggcgcctagtgtggatgctggggaggaagcggcagagccgagcgcgtcc  1381 
      P  V  I  P  Q  H  E  P  Q  A  P  E  L  L  Q  Q  A  R  E  Y   
 
Fig. 6.  Nucleotide and deduced amino acid sequences of Equine NF-B2. Full length 
equine NF-B2 was cloned, and sequenced. The open reading frame is shown in black. 
The grey shaded amino acid shows the alternatively spliced region that results in an 
alanine indel. The stop codon is shown by *. The 4 bold italic highlighted amino acids at 
the middle and at the end show the start and end of N-terminus and C-terminus of 
internal fragment, respectively. 
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1382  cccgtgatccctcagcacgaaccacaggccccggagctgctgcagcaggcccgggagtac  1441 
      N  E  R  L  F  G  L  A  R  R  S  A  R  A  L  L  D  Y  G  V   
1442  aacgagcgcctgttcggcctggcgcggcgcagcgcccgagccttgctcgactacggcgtc  1501 
      T  A  D  A  R  A  L  L  A  G  Q  R  H  L  L  T  A  Q  D  E   
1502  acagcggacgcgcgcgcgctgctggcgggacagcgccacctgctgaccgcgcaggacgag  1561 
      N  G  D  A  P  L  H  L  A  I  I  H  G  Q  T  S  V  I  E  Q   
1562  aacggagacgcgccgctacacctggccatcatccatgggcagaccagtgtcatcgagcag  1621 
      I  A  H  V  I  Y  H  A  Q  H  L  G  V  V  N  L  T  N  H  L   
1622  atagctcacgttatctaccatgcccagcacctcggcgttgtcaatctcaccaaccacctg  1681 
      H  Q  T  P  L  H  L  A  V  I  T  G  Q  T  R  V  V  S  F  L   
1682  caccagacacccctgcatctggcagtgatcaccgggcagacaagggtggtgagcttcctg  1741 
      L  Q  V  G  A  D  P  A  L  L  D  R  H  G  D  S  A  V  H  L   
1742  ctgcaggtaggcgcagacccggcactgctggatcggcacggagactcagcggtgcacctg  1801 
      A  L  R  V  G  A  G  A  P  D  L  L  R  A  L  L  Q  S  G  V   
1802  gcactgcgggtgggtgctggcgccccagacctgctgcgtgccctgctgcagagtggggtt  1861 
      P  A  M  P  Q  L  L  H  L  P  D  F  E  G  L  Y  P  V  H  L   
1862  cccgccatgccccagctgttgcacctgccggactttgaagggctgtacccagtacacctg  1921 
      A  V  R  A  R  S  P  E  C  L  D  L  L  V  D  N  G  A  E  V   
1922  gcggtccgtgcccggagccctgagtgcctagatctgctggtggacaatggggctgaagtg  1981 
      E  A  A  E  R  Q  G  G  R  T  A  L  H  L  A  T  E  M  E  E   
1982  gaggctgcagagcggcaggggggccgaacagccctgcatctggccaccgagatggaagag  2041 
      L  G  L  V  T  H  L  V  T  K  L  R  A  N  V  N  A  R  T  F   
2042  ctggggttggtcacccatctggtcaccaagctccgtgccaatgtgaatgcccgcactttc  2101 
      A  G  N  T  P  L  H  L  A  A  G  L  G  S  P  T  L  T  R  L   
2102  gcgggaaacacacccctacacctggcagccggactgggatccccaactcttacccgcctc  2161 
      L  L  K  A  G  A  D  I  H  A  E  N  E  E  P  L  C  P  L  P   
2162  cttctaaaagctggtgctgatatccatgcagagaatgaggagcccctgtgcccactgcct  2221 
      S  P  P  T  S  D  S  D  S  D  S  E  G  P  E  R  D  I  R  S   
2222  tcaccgcccacctctgatagtgactcagactctgaggggcctgagagggacatccgaagt  2281 
      S  F  R  G  H  T  P  L  D  L  T  R  S  S  K  V  K  T  L  L   
2282  agcttccggggccacacacctcttgacctcactcgtagcagcaaggtgaagaccttgctg  2341 
      L  N  A  A  Q  D  T  M  A  P  P  L  T  P  P  S  P  A  G  P   
2342  ctaaatgctgctcaggacaccatggcgccccccctgactccacccagccctgcaggacca  2401 
      E  L  P  L  E  D  T  V  L  Q  N  L  E  H  L  L  D  G  P  G   
2402  gagctgccactcgaggatacagtcctgcagaacctggagcatctgctagatgggccagga  2461 
      A  Q  G  S  W  A  E  L  A  E  R  L  G  L  R  S  L  V  D  T   
2462  gcccagggcagctgggcagagctggcagaacggctggggctacgcagtctggtggacacg  2521 
      Y  R  K  T  A  S  P  S  G  S  L  L  R  S  Y  K  L  A  G  G   
2522  tatcgaaagacagcctcacccagtggcagcctcctgcgcagctacaagctggctggtggg  2581 
      D  L  A  G  L  L  D  A  L  S  D  M  G  L  E  E  G  V  R  L   
2582  gacttggcaggcctgctggatgccctgtctgacatgggcctagaggagggagtgaggctg  2641 
      L  R  G  P  E  A  R  D  K  L  P  S  T  A  E  A  K  E  D  S   
2642  ctgcggggtcctgaggcccgagacaagctgcccagcacagcagaggcgaaggaggacagt  2701 
      A  Y  G  S  Q  S  V  E  Q  E  A  E  K  L  C  P  P  P  E  P   
2702  gcatatgggagccagtcggtggaacaggaggcagagaagctgtgcccaccccctgagcca  2761 
      P  G  G  L  C  H  G  H  P  Q  P  Q  V  H  *  T  V  T  H  S   
2762  ccaggagggctctgccatgggcacccacagcctcaggtgcactgaactgtcacccactca  2821 
      A  A  P  F  L  G  P  S  V  Q  H  P  P  I  P  V  L  I  *  H   
2822  gcagcccccttcctgggcccctctgtacagcatccccccattccagttcttatttaacac  2881 
      P  M  P  T  P  Q  L  G  Q  I  K  D  S  H  G  K  K  K  K  K 
2882  cccatgcccacccctcagctggggcaaataaaagattctcatgggaaaaaaaaaaaaaaa  2941 

2942    a 
 
Figure 6, continued.   
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Fig. 7. Amino Acid Alignment of Equine, Human, and mouse NF-B2. “*” indicates 
single and fully conserved residue. “:” shows conservation of strong groups. “.” 
illustrates conservation of weak groups. “ ” demonstrates no consensus. Rel homology 
domain, IPT_NF-B (DNA-binding) region, the ankyrin repeat region, ANK, region, are 
shown by black letters highlighted with grey, white letters highlighted with black, and  
white letters highlighted with grey, respectively. 

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Figure 7, continued.  
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CHAPTER III 
PROBING THE INTERACTION BETWEEN EIAV S2 PROTEIN AND EQUINE 
NF-B2 
Introduction 
Since EIAV S2 protein interacts with human NF-B2, is it possible that it also 
interacts with equine NF-B2? If EIAV S2 protein interacts with equine NF-B2 there is 
a possibility that EIAV uses NF-B2 pathway to evade the immune response and remain 
persistent in the infected equine. This might explain the role of S2 in EIAV 
pathogenesis. In order to investigate the interaction between EIAV S2 and NF-B2 
proteins, two different methods, the yeast two hybrid system and the co- 
immunoprecipitation process were used.  
Identification of the interaction of two proteins (in our case equine NF-B2 and 
EIAV S2) in the two hybrid system, which is an in vivo yeast-based system, is based on 
reconstitution of an active transcription factor. This active transcription factor is formed 
as a dimer between two fusion proteins, one of which contains a DNA-Binding Domain 
(DB) fused to the first protein of interest (DB-X; also known as the “bait”) and the other, 
an Activation Domain (AD) fused to the second protein of interest (AD-Y; also known 
as the “prey” or “target protein”). Interaction between DB-X and AD-Y, through the X 
and Y domain, generates a functional transcription factor that activates reporter genes, 
which are present in the chromosome of yeast strain MaV203. Activation of reporter 
genes is driven by promoters containing the relevant DB binding sites (Fig. 8). 
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Interaction of the bait (X) and prey (Y) is elucidated by analysis of series of reporter 
genes. For example, in yeast which contains HIS3 as the reporter gene, interaction 
between bait and prey proteins can be shown by growth of cells on plates lacking 
histidine. 
 
Fig. 8. The yeast two hybrid system. Interaction of two proteins generates a 
transcription factor that activates the reporter gene. 
 
Co-immunoprecipitation (Co-IP) is another method that was used to probe 
possible interactions between EIAV S2 and eq.NF-B2 proteins. This method recovers a 
protein together with its binding partner by using a specific antibody against one of the 
proteins, followed by recovery of the complex using protein G or A (depending on 
antibody species) attached to beads. Protein A and protein G are bacterial proteins that 
bind with high affinity to the Fc portion of various classes and subclasses of 
immunoglobulins from a variety of species. Then the result can be interpreted by 
western blot (Fig. 9). 
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Fig. 9. Co-immunoprecipitation procedures.  
 
Materials and Methods 
Yeast Two Hybrid System (Y2H) 
The bait plasmid was generated previously by cloning the S2 gene into pDEST 
32 (L. covaleda, unpublished data). A set of equine NF-B2 constructs  were cloned by 
recombination into the pDEST 22 vector in order to make the prey plasmid as described 
in the GatewayTM Technology manual. In brief, primers containing the attB1 (5-
ACAAGTTTGTACAAAAAAGCAGGCTNN-3) and attB2 (5-
ACCACTTTGTACAAGAAAGCTGGGTN-3) sequences were generated to add attB1 
and attB2 sites to the 5 and 3 ends, respectively, of  following fragments of equine NF-
B2: the 2498 bp internal fragment of equine NF-B2 (clone 3a); full length equine NF-
B2; and a fragment of equine NF-B2 similar to the human NF-B2 cDNA which was 
identified from the initial yeast two hybrid screening. A standard PCR was performed 
Incubation with 
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one of the protein 
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proteins 
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for each fragment to prepare the attB-PCR product. The PCR products were gel purified 
and 5 µl of each purified DNA was cloned into the pDONR™201 vector, an entry 
vector, using BP Clonase™ Enzyme. The entry vectors, containing equine NF-B2 
genes, were transformed into competent cells (Top 10 cells) to generate the entry clones. 
The cells were plated on LB plates containing 50 g/ml kanamycin and incubated for 
24h at 37 °C. Then entry clones were isolated and the vectors were recovered from the 
competent cells using an Eppendorf, FastPlasmidTM Mini kit. Equine NF-B2 genes were 
later transferred from Gateway® Entry Clones into pDEST™22 vectors using the LR 
recombination reaction to generate the destination vectors. The destination vectors were 
transformed into Top 10 cells and incubated at 37 °C for 24h. The vectors, containing 
the equine NF-B2 gene, were purified from cells using the Eppendorf FastPlasmidTM 
Mini kit. These vectors, which are known as prey plasmids, were introduced into the 
yeast strain MaV203.  
The bait and the prey plasmids were introduced into yeast strain MaV203 by 
transformation as follows: A colony of MaV203 was inoculated in 50 ml of YPAD, a 
rich, non-selective medium for the routine growth of yeast, and incubated  at 30 °C until 
the culture reached the OD600 of 2.0. Then the culture medium was centrifuged at 3000 g 
for 5 minutes. The yeast were suspended in 25 ml ultrapure H2O and centrifuged again. 
The yeast were then resuspended in 1 ml 100 mM Lithium Acetate (LiAc), and 
transferred to a 1.5 ml tube and then pelleted. Cells were resuspended in 400 µl of 100 
mM LiAc and aliquoted into 50 µl samples for individual transformation. Cells were 
pelleted and resuspended in 240 µl 50% polyethylene glycol (PEG) 3350. Then the 
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following components were added to the suspension and mixed with it gently: 36 µl 1M 
LiAc, 25 µl boiled calf thymus DNA (2.5 mg/ml), 48 µl H2O, and 0.1 µg/µl plasmids 
(prey and bait). The prey and bait plasmids are listed in Table 4. The suspension was 
incubated in water bath at 30 °C for 30 minutes followed by a heat shock at 40 °C for 20 
minutes. Then cells were pelleted and resuspended in 200 µl H2O. Each transformation 
was plated onto the selection plates containing uracil and histidine (SC-Leu-
Trp+Ura+His). The plates were incubated for 60 to 72 hours at 30 °C, until the yeast 
colonies became visible. After incubation, four different colonies from each 
transformation were patched on a single SC-Leu-Trp+Ura+His plate (master plate) along 
with two colonies each from yeast control strain A-E. The plates were incubated at 30 °C 
for about 18 hours. 
 The master plate was replicated onto different testing plates listed in Table 5 as 
described in the instruction manual of ProQuest Two-Hybrid System with Gateway 
Technology. Table 5 shows the set of tests that were conducted in order to determine if 
there was any interaction between EIAV S2 and equine NF-B2. Activation of the HIS3, 
URA3, and ß-Galactosidase reporter genes enables two-hybrid-dependent transcriptional  
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activation to be screened by cell growth on plates lacking histidine or uracil, and a 
change in the color of media from clear to yellow, respectively. Moreover, two hybrid-
dependent induction of URA3 converts the compound 5-fluoroorotic acid (5FOA) to 5-
fluorouracil, which is toxic. Therefore, cells in which the two proteins have interacted 
will grow on plates lacking uracil, and not on plates containing 5FOA. 
Controls were performed as follows: To assess the self-activation of AD-NF-
B2, the yeast was transformed with pDBLeu plasmid and AD-NF-B2. Yeast 
containing AD-NF-B2 and pDBLeu grows in the selective media and FOA plates. AD-
NF-B2 and pDBLeu do not induce any reporter gene expression. Further, the strength 
of the interaction between two proteins was determined by using a set of control strains 
provided by the GatewayTM system which contained plasmid pairs that express fusion 
proteins with a variety of interaction strengths. 
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Table 4  
Transformation of MaV203 by different bait and prey plasmids 
Transformation Bait Plasmid Prey Plasmid Purpose 
1 Control plasmid 
(pDBLeu) 
pDEST TM 22-eq. NF-B2 (any fragment) Self-activation 
control 
2 pDEST TM 32-S2 pDEST TM 22-eq. internal fragment of NF-B2   Interaction test 
for S2 and equine 
NF-B2 
3 pDEST TM 32-S2 pDEST TM 22- full length eq.NF-B2 Interaction test 
for S2 and equine 
NF-B2 
4 pDEST TM 32-S2 pDEST TM 22- equine NF-B  similar to the human NF-B2 
cDNA, identified from Y2H, (using two different splice 
variants)  
Interaction test 
for S2 and equine 
NF-B2 
5 pDEST TM 32-S2 pDEST TM 22-human NF-B2 (the fragment that identified from 
the initial yeast two hybrid screening) 
Positive control 
 
Table 5  
Set of tests for screening yeast two-hybrid-dependent transcription activation 
                                                                       
 
Test HIS3 induction URA3 induction URA3 induction ß-Galactosidase induction 
Assay Histidine auxotrophy 5FOA sensitivity Uracil auxotrophy X-gal assay 
Plates used SC-Leu-Trp-His+3AT SC-Leu-Trp+5FOA SC-Leu-Trp-Ura Yeast ß-Galactosidase 
assay kit 
Concentrations 10 mM 3AT 25 mM 3AT 0.2% 5FOA No Uracil Not applicable 
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Co-immunoprecipitation (Co-IP) 
To facilitate Co-IP assays, different versions of equine NF-B2 were cloned into 
the pcDNATM 3.2/V5-DEST vector.  The vector expresses a V5 tag sequence which can 
be fused to the gene of interest. We tagged full length  equine NF-B2, or a fragment of 
equine NF-B2 similar to the human NF-B2 cDNA which was identified from the 
initial yeast two hybrid screening (using two different splice variants). In order to clone 
the NF-B2 into the vector, it was first cloned into an entry vector such as pDONR 201 
vector. Afterwards, the Gateway LR clonaseTM Enzyme Mix was used to introduce the 
NF-B2 to the pcDNATM 3.2/V5-DEST vector by recombination. The procedure for 
cloning is described in the GatewayTM Technology manual. 
Chinese hamster (CHO-K1) ovary cells were transfected with GFP-S2 and 
equine NF-B-V5 using Invitrogen LipofectaminTM 2000. In brief, the procedure was as 
follows; CHO-K1 cell line was cultured in HYQ MEM Alpha Modification 1X (Cat. 
Sh3026565.01) containing 1% (v/v) penicillin, 10% fetal bovine serum (FBS), and 1% 
NEAA (non-essential amino acids), and incubated at 37°C in a 5% CO2 atmosphere 
incubator. One day before transfection, 6 × 105 cells were seeded per well of a 6-well 
plate in 2ml of complete growth medium, and incubated at 37°C in a 5% CO2 
environment. Cells were incubated until they became 80% to 90% confluent, which 
generally took 18 to 24 hours. On the day of transfection, the complete growth medium 
was removed from the plates and replaced with 2 ml of complex of transfection medium 
without serum (Opti-MEM I Reduced Serum Medium) containing 5 µl of 
LipofectaminTM 2000 and 4 µg DNA plasmid (GFP-S2 or NF-B- V5). Then the cells 
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were incubated with this complex for 4 to 6 hours at 37°C in a 5% CO2 environment. 
After the incubation time, the transfection medium was replaced by the original 
complete growth medium. After 24 to 48 hours, the cells were harvested and washed one 
time with PBS. To extract the protein, the cells were resuspended in the 500 µl lysate 
buffer containing 1X Halt Protease Inhibitor and incubated for 5 minutes on ice.  In 
order to have only the lysate of CHO-K1 cells, as a control which will be explained later, 
one well of cells was kept untreated.   
We also examined possible interaction of EIAV S2 with endogenous equine NF-
B2. Western blots using antibody to human NF-B2 were performed to assay the 
lysate.   
Co-immunoprecipitation of NF-B- V5 or endogenous NF-B 2 with GFP-S2  
In a 1.5 ml tube, an aliquot of NF-B- V5 or endogenous NF-B 2 and GFP-S2 
were incubated with a binding buffer overnight on a rocker at 4 oC. Then the antibody 
for detecting one of the tags (mouse -GFP or mouse -V5) was added to the tube and 
incubated for two hours at room temperature or overnight at 4 oC with rotation. During 
this time, the antibody bound to the tag. Sixty µl immobilized protein G-agarose beads 
(Pierce) was added to immune complexes and incubated for 2 hours at room temperature with 
rotation. Then the beads were collected using a Pierce HandeeTM spin cup-paper filter 
(Prod # 69700) and washed 4 times with washing buffer (PBS, 8mM Na2PO3, 2mM 
K2PO3, 140mM NaCl, 10mM KCl, pH 7.4). After washing the beads, the elution buffer 
(0.1 M glycine pH 2-3) was added to the spin column. After 5 minutes of incubation at 
room temperature, the spin column was centrifuged. The eluted components were loaded 
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on 10% SDS-PAGE gels and transferred to nitrocellulose. Membranes were incubated 
with mouse anti-V5 or mouse anti-GFP antibodies, followed by  incubation with anti-
mouse HRP TrueBlot (ebioscience), to eliminate interference of immunoprecipitating 
immunoglobulin heavy and light chains. Immunoreactive bands were visualized by 
enhanced chemiluminescence (West Femto; Pierce). 
A set of controls were performed for co-immunoprecipitation as follows: To 
ensure that both proteins partners were present in cell lysates, aliquots of cell lysates 
were run on SDS PAGE and probed by Western blot with appropriate antisera. To 
ensure proper washing of the beads (removal of unbound material), the last wash was 
analyzed by SDS PAGE and probed by Western blotting. To control for absence of non 
specific interactions, NF-B p100 containing lysates were incubated with GFP alone, 
followed by a pull down with anti-GFP. NF-B and GFP-S2 were also incubated with 
protein G alone in control reactions.  
In order to analyze the presence of the proteins in the eluted fragment, the 
western blot technique was used. First, all samples were denatured by heating them for 5 
minutes at 95oC. Then the proteins were separated on 10% SDS-polyacrylamide gels and 
electroblotted to a nitrocellulose (NC) membrane. Then the membrane was blocked with 
5% non-fat milk for 1 hour at room temperature. After blocking, the membrane was 
incubated with either anti- GFP or anti- V5, followed by peroxidase-conjugated 
secondary antibodies, and detected by chemiluminescence. Between the incubation with 
two antibodies and also before the detection, the membrane was washed 4 times as 
follows: once with Tris- buffered saline (TBS) for 5 minutes, two times with Tris- 
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buffered saline containing 0.05% Tween 20 (TBST), each time for 10 minutes, and 
finally with TBS for 5 minutes. Controls for western blots were equine NF-B- V5 or 
endogenous equine NF-B 2 and GFP-S2.  
Results 
Analysis of interaction between EIAV S2 and Equine NF-B2 in yeast two hybrid system 
To study the interaction of EIAV S2 and equine NF-B2, pDEST TM 32-S2 and 
pDEST TM 22-eq.NF-B2  were introduced to yeast strain MaV203 by transformation as 
described in Table 4. Four different equine NF-B2 constructs were used. Detailed 
results are shown in Table 6.  None of the tested constructs was found to interact with 
EIAV S2. As shown in table 6, an interaction between EIAV S2 and human NF-B2 was 
used as a positive control.  
Analysis of interaction between EIAV S2 and Equine NF-B2 using Co-
immunoprecipitation (Co-IP) 
As there was not any detectable interacting between EIAV S2 and equine NF-
B2 in the yeast two hybrid system, a second methods, co-immunoprecipitation, was 
used to detect EIAV S2/eq. NF-B2 interaction. For this propose, we tried to 
immunoprecipitate GFP-S2 with NF-B- V5 or with endogenous equine NF-B2 as 
described in methodology. Examples of IP results using different versions of equine NF-
B2 in constructions with GFP-S2 are shown in Fig. 10. In all results shown, both GFP-
S2 and NF-B-V5 were detected in flow through samples and there was no detectable 
protein in terminal washes. Under all tested conditions, only GFP-S2 was detected 
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elution samples. We were not able to see any band in the elution samples that 
corresponds to the endogenous eq.NF-B2 or eq.NF-B-V5 (different sizes). The 
controls indicate that our Co-IP system did work correctly but that EIAV S2 and equine 
NF-B2 did not interact with each other under the conditions used (Fig. 10).  
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Table 6 
Result of the Interaction between EIAV S2 and equine NF-B in the Yeast Two Hybrid System 
*Middle fragment (3a), Full length, similar to Human fragment which pulled of from Y2H (different splice variants).
Test HIS3 induction URA3 induction URA3 induction ß-Galactosidase induction 
Plates used SC-Leu-Trp-
His+3AT 
SC-Leu-Trp+5FOA SC-Leu-Trp-Ura Yeast ß-Galactosidase assay kit 
Concentrations 10 mM 3AT 
25 mM 3AT 
0.2% 5FOA No Uracil Not applicable 
Result of the Interaction 
between EIAV S2 and 
equine NF-B2 (different 
fragment)* 
 
No growth 
 
Growth 
 
No growth 
 
Negative 
             
Negative control 
(yeast strain A) 
No growth 
 
Growth 
 
No growth 
 
Negative 
 
Strong Positive control 
(yeast strain E) 
Growth 
 
No growth 
 
Growth 
 
positive 
 
Positive control 
(S2 and Hum. NF-B2 
Growth 
 
Growth 
 
No growth 
 
positive 
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Fig. 10. Co-IP assay to probe the interaction of EIAV S2 and equine NF-B2. The 
amount of each protein and the procedure for each Co-IP is illustrated beside each 
western blot. Flow through samples are designated by (Ft.), wash samples by (W), elute 
samples by (E) and positive control by (+ control). Full length of equine NF-B2, 
endogenous equine NF-B2, and a fragment of equine NF-B2 similar to human NF-
B2 which was pulled from Y2H assay were used to probe the interaction with S2, 
panels A-C, respectively. 
* Both splice variants were tested.
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CHAPTER IV 
EXPRESSION OF NF-B2 IN EQUINE MACROPHAGE 
Introduction  
As NF-B2 is an important component of immune response, and EIAV is a 
macrophage- tropic virus, it was important for us to examine NF-B2 expression in 
eMDM. Moreover, we were interested to see if EIAV influences NF-B2 expression in 
these cells. To analyze NF-B2 gene expression, the northern blot, Reverse-
Transcriptase-PCR (RT-PCR), and quantitative PCR methods were used.   
Materials and Methods  
Primary equine monocyte- dreived macrophages (eMDM) were established as 
described previously.  The Qiagen Rneasy®® Mini kit was used to extract total RNA at 
various times post plating. The collected RNAs were used either for generating cDNA or 
for northern blots.  
Northern Blot 
A Northern blot assay was conducted to reveal possible splice variants of equine 
NF-B2. In brief the procedures were as follows: RNA was isolated from eMDM from 
day one to day four post plating using Qiagen RNeasy® Mini kit, exactly according to 
the manufacturer’ s instructions. One  microgram of each RNA sample in 12 l of 
loading buffer (50 l of formamide, 16.6 l of 37% formaldehyde, 10 l of 10X MOPS, 
2 l of 2.5% Bromphenol blue, 11.4 l diethyl pyrocarbonate [DEPC]-treated double 
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distilled (dd) H2O) was denatured at 65 °C for 15 minutes and chilled on ice for 1 
minute. Then the denatured RNA samples were loaded on a 1% agarose gel containing 
2% formaldehyde and electrophoretically separated at 50 V in 1X MOPS running buffer 
(10X MOPS: 0.4 M Morpholinopropanesulfonic acid (free acid); 0.1 M Na-acetate-3 x 
H2O; 10 mM EDTA; adjusted to pH 7.2 with NaOH) for about 3 hours. Prior to blotting, 
the gel was rinsed one time with ddH2O and later rinsed for 2 times for 15 minutes each 
time in 20X SSC (0.3 M sodium chloride and 0.03 M sodium citrate). RNA was 
transferred overnight to a positively charged nylon membrane (BrightStar®-Plus, cat. # 
AM10102) by upward capillary action using 20X SSC. After blotting, membrane was air 
dried, and washed in 5X SSC which contained 0.5 % SDS at room temperature for 10 
minutes. Then RNA was crosslinked to the nylon membrane with a UV cross-linker. The 
membrane was rinsed two times in 2X SSC + 0.1% SDS and was prehybridized with 
8ml Ambion ultrasensitive hybridization buffer (ULTRAhyb® cat # 8669, 8670) for 4 
hours at 50 °C with gentle agitation in a water bath shaker. Meanwhile, a biotinylated 
DNA probe was made from the 5 end of equine NF-B2 according to Ambion’ s 
BrightStar Psoralen-Biotin Labeling Kit (cat # 1480). The probe was first tested at 
different concentrations to ensure that it was detectable (Fig. 11). The probe then was 
diluted 10-fold with 10 mM EDTA and denatured at 90°C for 10 minutes. The denatured 
probe was added directly to the hybridization buffer. After prehybridization of the 
membrane, it was hybridized with probe/hybridization (240ng/4ml) mixture and 
incubated overnight. The membrane was then washed 2 times for 15 minutes each time 
in a 2X SSC containing 0.1% SDS at room temperature followed by 3 times for 30 
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minutes each at 60 °C  in 0.1X SSC containing 0.1% SDS. Immunological detection of 
the probe was done exactly in the same manner as described in DIG High Prime DNA 
Labeling and Detection Starter Kit II protocol (cat. # 11585614910). The only difference 
was that Streptavidin-Alkaline Phosphatase was used instead of Anti-Digoxigenin- 
Alkaline Phosphatase Conjugate.  
PCR and quantitative real-time PCR 
Standard PCR and quantitative PCR were used to check the expression of equine 
NF-B2 in uninfected eMDM cells and  in eMDM cells infected with  EIAV 17b (wild 
type) or EIAV S2 (S2 is knock out) virus. eMDM were established in 12-well plates at 
4x105 cells/well and incubated for 2 days at 37 °C in 5% CO2. At 2 days post plating, 
EIAV 17b or EIAV S2 (containing 5000 cpm of RT activity) were added to each well 
of eMDM. At 4, 24, 48, 72, and 120 hpi, eMDM were washed with PBS, harvested with 
10mM EDTA/PBS, and total RNA was extracted by using the Qiagen RNeasy®® Mini 
kit. First strand cDNA was made for either standard PCR or quantitative PCR, from each 
set of total RNA, as described previously. Short NF-B (forward and reverse) primers 
[Table 1] were used for standard PCR to amplify the cDNA. PCR conditions for 
amplifying equine NF-B2 cDNA were as follows: one initial denaturation at 94 °C for 
3 minutes, thirty cycles at 94 °C for 30 sec, 62 °C for 30 sec, and 72 °C for 1 minute and 
40 sec, followed by a final extension at 72 °C for 5 minutes.  For quantitative PCR, 
applied Biosystem’ s Assaysby-DesignSM Service was used to generate a set of Custom 
TaqMan® Gene Expression Assays of primer and probe sets for equine NF-B2 and 18S 
RNA. The sequences of the forward and reverse primers and the probe are listed in table 
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7. The PCR reactions containing Custom TaqMan® Gene Expression Assays Mix 
(containing primers and probe), TaqMan® Universal PCR Master Mix (containing Taq, 
dNTPs and buffer), No AmpErase® UNG (final concentration 1X), and cDNA in a 
volume of 20 l were prepared and placed in 96-well plates. The samples were amplified 
in an automated fluorometer (ABI 7500 Sequence Detection System, Applied 
Biosystems) under the following conditions: 2 minutes at 50 °C, 10 minutes at 95 °C, 
followed by 40 cycles of 15 sec at 95 °C and 1 minute at 60 °C. Comparative threshold  
cycle (Ct) method was used to analyze the raw data. The value for each sample from 
infected cells and uninfected cells was normalized using 18S, a housekeeping gene (Li et 
al., 2000).  
 
Table 7  
Primers and probes for quantitative PCR 
Probes are labeled with 5 6FAM, fluorescent dye 6-carboxyfluorescein, and 
3MGBNFQ.
Primer Sequence 
eNF-Bp100-49 forward 5-TGTCTGTGGGACCCAAGGA-3 
eNF-Bp100-49 reverse 5-CATGCAGGACACCCAGGTT-3 
eNF-Bp100-49 probe 5-ATGACTGCCCAATTTAA-3 
18S forward 5-AAACGGCTACCACATCCAA-3 
18S reverse 5-TCGGGAGTGGGTAATTTGC-3 
18S probe   5-AAGGCAGCAGGCGC-3 
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Results 
Analysis of equine NF-B2 transcripts by Northern blot 
In order to directly analyze equine NF-B2 transcripts, one l aliquots of total 
RNA extracted from eMDM at one day to four days post-plating were purified and used 
for northern blotting. As seen in Fig. 11 one major transcript of approximately 4.5 kb 
was present in all samples. Expression of this transcript decreased over 4 days. The 
observed transcript was larger than expected (the expected size was about 3 kb) based on 
the recovery cDNAs by PCR. The blot shows no evidence of splice variants not detected 
by PCR. 
EIAV infection up regulates expression of NF-B2 
Based on preliminary data suggesting an interaction between the EIAV S2 
protein and human NF-B2, eMDM cells were infected with EIAV17b or EIAVS2 to 
determine if infection had effect on NF-B2 expression. Total RNA from infected and 
uninfected eMDM cells were collected at different days. First strand cDNA was made 
from each RNA and used for PCR or quantitative PCR. The results of a standard PCR 
assay suggested that in uninfected cells the expression of NF-B2 is decreased after 3 
days post plating, about the time that monocytes start to differentiate. Interestingly in 
EIAV infected eMDM the expression level of NF-B2 appeared to be somewhat 
variable (Fig. 12, A). To validate these data, quantitative real-time PCR was used. The 
signal from 18S, a housekeeping gene, was used to quantify the relative of target gene 
(equine NF-B2) in each sample (infected versus uninfected). By using the comparative 
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threshold cycle (Ct) method (Li et al., 2000) the raw data was analyzed and the value for 
each sample was normalized using 18S. Comparison the expression of NF-B2 in 
infected versus uninfected cells suggests that EIAV induces the expression of equine 
NF-B2 in the eMDM (Fig. 12, B). We did not detect a significant difference between 
NF-B2 expression levels in cells infected with wild type versus S2 deleted virus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11. Analysis of equine NF-B2 transcripts by Northern blot. One g aliquots of 
total RNA extracted from eMDM at one day to four days post-plating were purified and 
used for northern blot. As it can been in Fig. 12 one major transcript of approximately 
4.5 kb was seen in all samples. 
 
1d             2d              3d          4d 
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Fig. 12. EIAV infection up regulates expression of NF-B2. (A) Results of standard 
PCR to detect NF-B2 gene experssion. (B) Quantitative real time PCR was performed 
to quantify NF-B2 gene expression. Values of each time point were  normalized using 
18S rRNA levels. 
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CHAPTER V 
SUMMARY AND CONCLUSIONS 
 
EIAV S2 gene expression is essential for viral replication and disease expression 
of EIAV in vivo (Fagerness et al., 2006; Li et al., 2000). One method for determining the 
role of S2 in pathogenesis is to identify the cellular proteins that interact with S2. In our 
laboratory, due to lack of an equine cDNA library, a commercially available human 
spleen cDNA library was used in a yeast two hybrid screen to elucidate any possible 
interactions between cellular proteins and S2. Interestingly, three potential proteins were 
found that interacted with EIAV S2. Nuclear Factor Kappa B p100/p52 (NF-B2) was 
one those proteins. NF-B2 has a significant role in the regulation of immune and 
inflammatory responses, is involved in a variety of viral diseases and also is a target for 
many pathogenic viruses such as HIV-1 (Santoro et al., 2003; Tato et al., 2002). 
Therefore, we thought it would be significant to check for any possible interaction 
between EIAV S2 and equine NF-B2.  
In order to investigate the interaction between S2 and equine NF-B2, we cloned 
and sequenced equine NF-B2, for the first time, in our laboratory. Two splice variants of 
equine NF-B2 that were similar to reported human NF-B2 splice variants were 
detected. There was about 95% amino acid sequence homology between equine and 
human NF-B2. However, we found the greatest difference, with only 90% amino acid 
similarity, at the ankyrin repeat region (ANK), which is the location where interaction 
between two proteins takes place.  
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We tested for possible interaction between EIAV S2 and equine NF-B2 using 
two different methods, the yeast two hybrid system and co-immunoprecipitation. 
Interestingly, neither the yeast two hybrid screening nor the co-immunoprecipitation 
method showed any interaction between EIAV S2 and equine NF-B2. Since, human NF-
B2 and equine NF-B2 are not 100% similar, there is a possibility that S2 interacts with 
the section of the human NF-B2 which is not identical to the equine NF-B2. Moreover 
the interaction between S2 and human NF-B2 is a weak interaction (based on yeast two 
hybrid results). Therefore, there might be also an interaction between S2 and equine NF-
B2, however it is too weak to be detected by the yeast two hybrid system or the co-
immunoprecipitation method. We attempted to check the interaction using the co-IP 
system with a cross linker (data not shown), however the system did not work as it should 
have worked and hence we could not get any useful results.  
 Although no interaction was detected between EIAV S2 and equine NF-B2, 
we were interested to know how NF-B2 is expressed in eMDM and whether EIAV has 
any effect on its expression. After analyzing the expression of equine NF-B2 using 
northern blot or RT-PCR, we found that the greatest amount of equine NF-B2 
expression in eMDM cells was in the monocyte stage. As monocytes differentiated to 
macrophages, the level of NF-B2 expression was reduced. However, in infected eMDM 
cells, the level of NF-B2 expression in the macrophage stage remained at the same level 
as monocyte stage, which suggests that EIAV up regulates the expression of NF-B2.  
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